LIT-002

LIT-002
Clinical data
Other namesLIT002
Drug classOxytocin receptor agonist; Vasopressin V2 receptor agonist
Identifiers
  • (2S,4R)-2-(dimethylcarbamothioyl)-4-[4-(hydroxymethyl)triazol-1-yl]-N-[[2-methyl-4-(1-methyl-4,10-dihydropyrazolo[4,5-c][1,5]benzodiazepine-5-carbonyl)phenyl]methyl]pyrrolidine-1-carboxamide
PubChem CID
ChEMBL
Chemical and physical data
FormulaC31H36N10O3S
Molar mass628.76 g·mol−1
3D model (JSmol)
  • CC1=C(C=CC(=C1)C(=O)N2CC3=C(NC4=CC=CC=C42)N(N=C3)C)CNC(=O)N5C[C@@H](C[C@H]5C(=S)N(C)C)N6C=C(N=N6)CO
  • InChI=1S/C31H36N10O3S/c1-19-11-20(29(43)39-15-22-14-33-38(4)28(22)34-25-7-5-6-8-26(25)39)9-10-21(19)13-32-31(44)40-17-24(12-27(40)30(45)37(2)3)41-16-23(18-42)35-36-41/h5-11,14,16,24,27,34,42H,12-13,15,17-18H2,1-4H3,(H,32,44)/t24-,27+/m1/s1
  • Key:QZVVCUZGIWAQFK-SQHAQQRYSA-N

LIT-002 is a small-molecule oxytocin receptor agonist which is under investigation for potential medical use, with possible indications including autism, drug addiction, and neuropathic pain.